Navigation Links
Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2012 at 5:00 p.m. ET / 2:00 p.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The presentation and break-out session will be webcast through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording will be made available following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California and has a commercial manufacturing facility in Ohio. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin and Lilly Set Date and Time for Conference Call
2. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
3. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
7. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
8. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
9. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
10. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
11. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 Adult stem ... therapies are biological, but not magical. However, ... to treat them as if they were magical. ... unsanctioned studies that constitute “stem cell tourism,” are ... approach to developing new regenerative medicine therapies. In ...
(Date:7/22/2014)... (PRWEB) July 23, 2014 The ... , The goal of the Symposium is ... spectrum of scientists working in the biomaterials field, ... that represent the most promising directions for ultimate ...     Provide faculty and government scientists with ...
(Date:7/22/2014)... Even within a phylum so full of mean little creatures, ... for its cruelty -- at least to crickets. Native to ... a most predatory sort of parasite. It swoops onto the ... larvae, and leaves its wicked brood to invade, kill and ... this would be possible without the fly,s ability to find ...
(Date:7/22/2014)... Vibrate a solution of rod-shaped metal nanoparticles in water ... like tiny drill bits. Why? No one yet knows ... and Technology (NIST) have clocked their speedand it,s fast. ... rotate 10 times faster than any nanoscale object submerged ... dizzying rate has opened up the possibility that they ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2
... Oct. 12 Spherix Incorporated (Nasdaq: SPEX ... metabolic syndrome and atherosclerosis; and providers of technical and ... companies, today announced the close of previously reported agreements ... B Convertible Preferred Stock and warrants to purchase shares ...
... 12 US Oncology, Inc., the nation,s ... enrolled the 1,000th patient in a Phase I clinical ... Phase I clinical trials present special challenges, including increased ... trial designs, and some first-in-human trials, making Phase I ...
... SCOTTSDALE, AZ, Oct. 12 /PRNewswire/ - Dynamic Ventures ... the Editorial Board of Standard and Poor,s ("S&P") ... Records Market Access Program. Standard & Poor,s Corporation ... on U.S. and international public companies by investors ...
Cached Biology Technology:Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 2Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5Dynamic Ventures Corporation's Information To Be Available Through Standard & Poor's Market Access Program 2
(Date:7/23/2014)... are packed with healthful compounds, and now lab tests ... as prescription anti-diabetic medication, scientists report. In their new ... Food Chemistry , they found that how the herbs ... which compounds contribute the most to this promising trait. ... that in 2012, type-2 diabetes affected more than 8 ...
(Date:7/23/2014)... Basement membrane degradation and blood-brain barrier damage ... and brain functioning. Matrix metalloproteinase-9 is able ... basement membrane around cerebral blood vessels and ... Huilian Hou and colleagues from the First ... Jiaotong University, China induced cerebral infarction in ...
(Date:7/23/2014)... hippocampal region of the brain is important ... However, the underlying mechanisms are unclear. Dr. ... China monitored the activity of hippocampal neurons ... the mechanisms underlying the neuronal responses. Somatosensory ... changed local field potentials into theta rhythm-dominated ...
Breaking Biology News(10 mins):
... Attendance on Demand,web-hosted employee time and attendance service ... time clock. The unique data,collection device is Internet-ready, ... the web hosted employee time tracking system,Attendance on ... complex set-up,needed., The HP WebNet, available exclusively ...
... developed a potentially powerful new tool in the fight ... diseases, including blindness, in 40 million children annually, and ... in developing countries. This tool consists of ... corn that will enable developing countries to identify and ...
... species are those that occur outside their natural range ... They can be plants, animals or microorganisms that are ... through tourism, travel or trade, or when domestic animals ... to the rising cost of invasive species on a ...
Cached Biology News:Web-Hosted Attendance on Demand(R) Introduces Innovative Web Time Clock 2New way to produce high-vitamin corn could improve nutrition in developing countries 2New way to produce high-vitamin corn could improve nutrition in developing countries 3Scientists call for urgent research into 'real' impacts of invasive species 2Scientists call for urgent research into 'real' impacts of invasive species 3
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Parathyroid Hormone Receptor 2 [PTHR2]...
... Desalt Spin Columns contain a proprietary high-performance ... exceptional desalting and protein-recovery characteristics compared to ... low as 25 g/ml of protein can ... > 95% retention of salts and other ...
Biology Products: